Tag: clinical trial
First Patient Dosed in Phase 1 Clinical Trial of ADC Therapeutics’...
A first patient has been dosed in a Phase 1 clinical trial evaluating ADCT-901, targeting kidney-associated antigen 1 (KAAG1), in patients with selected advanced...
New Phase I Study Investigates [Vic-]Trastuzumab Duocarmazine + Niraparib in HER2-Expressing...
As part of a new study focusing on advanced targeting human epidermal growth factor receptor-2 (HER2-) expressing cancers, including locally advanced or metastatic solid...
Institutional Review Board Approves Phase I Trial with GTB-3550
The University of Minnesota's Institutional Review Board (IRB) and Cancer Protocol Review Committee (CPRC) has granted GT Biopharma (Westlake Village, CA 91362), permission to...
First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...
Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...
Eric Rosenthal Reports: Why Academia Wasn’t Ready to Build Big Data...
Big news hit the pharmaceutical industry in February when Roche Pharmaceuticals announced that it would be acquiring big-data firm Flatiron Health for $1.9 billion.
Roche...
Lifastuzumab Vedotin is Well-tolerated + Improves Objective Response Rate in Phase...
Lifastuzumab vedotin, also known as DNIB0600A (RO5541081) and RG-7599, is an antibody-drug conjugate or ADC.
In clinical trials the investigational drug is compared to pegylated...
First Patient with Advanced Solid Tumors with HER2 Expression Dosed in...
A first patient with advanced solid tumors with HER2 Expression was dosed in a phase I clinical trial with ADCT-502. The investigational drug being...
Phase I/II Clinical Trial of Vadastuximab Talirine Initiated in Patients with...
Earlier today Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, confirmed that...
Seattle Genetics Completes Enrollment for Phase III Trial Designed to Evaluate...
Seattle Genetics and its collaborator, Takeda Pharmaceutical, have completed patient enrollment in the open label, phase III ALCANZA (NCT01578499) clinical trial. This randomized trial is...
Sacituzumab govitecan (IMMU-132) Shows Positive Interim Phase II Results
Sacituzumab govitecan also known as IMMU-132, an antibody-drug conjugate being developed by Immunomedics, a clinical-stage biopharmaceutical company, continues to produce durable responses in patients with...
